Kleiton Silva Borges, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Adrenal Cortex Neoplasms | 7 | 2023 | 157 | 1.840 |
Why?
|
Adrenocortical Carcinoma | 5 | 2023 | 85 | 1.530 |
Why?
|
Supratentorial Neoplasms | 3 | 2023 | 158 | 1.160 |
Why?
|
Ependymoma | 3 | 2023 | 319 | 1.020 |
Why?
|
Transcription Factor RelA | 3 | 2023 | 250 | 0.760 |
Why?
|
Phthalazines | 3 | 2021 | 370 | 0.750 |
Why?
|
beta Catenin | 3 | 2023 | 1035 | 0.660 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2020 | 2887 | 0.610 |
Why?
|
Protein Kinase Inhibitors | 4 | 2020 | 5609 | 0.540 |
Why?
|
Benzamides | 4 | 2021 | 1341 | 0.540 |
Why?
|
Receptors, Notch | 1 | 2019 | 734 | 0.480 |
Why?
|
Glioblastoma | 4 | 2020 | 3451 | 0.460 |
Why?
|
Neoplastic Stem Cells | 1 | 2019 | 1341 | 0.380 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2013 | 345 | 0.370 |
Why?
|
Apoptosis | 10 | 2020 | 9425 | 0.350 |
Why?
|
Dacarbazine | 2 | 2013 | 559 | 0.340 |
Why?
|
Quinazolines | 2 | 2013 | 1350 | 0.320 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2011 | 615 | 0.300 |
Why?
|
Antineoplastic Agents | 8 | 2020 | 13531 | 0.270 |
Why?
|
Cytidine | 2 | 2016 | 66 | 0.250 |
Why?
|
DNA Modification Methylases | 2 | 2016 | 204 | 0.240 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 1509 | 0.230 |
Why?
|
Glypicans | 1 | 2023 | 34 | 0.230 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2021 | 8359 | 0.210 |
Why?
|
Drug Synergism | 5 | 2021 | 1731 | 0.200 |
Why?
|
Adrenal Insufficiency | 1 | 2023 | 190 | 0.200 |
Why?
|
Disease Models, Animal | 1 | 2020 | 17831 | 0.190 |
Why?
|
Cell Proliferation | 8 | 2021 | 10303 | 0.180 |
Why?
|
Medulloblastoma | 2 | 2016 | 676 | 0.180 |
Why?
|
Leukemia, Lymphoid | 1 | 2020 | 309 | 0.180 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2020 | 98 | 0.170 |
Why?
|
Cell Line, Tumor | 11 | 2021 | 16652 | 0.170 |
Why?
|
Wnt Proteins | 1 | 2023 | 719 | 0.170 |
Why?
|
Adrenal Hyperplasia, Congenital | 1 | 2020 | 102 | 0.170 |
Why?
|
Mitotane | 1 | 2017 | 18 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11539 | 0.150 |
Why?
|
Brain Neoplasms | 4 | 2015 | 8830 | 0.150 |
Why?
|
Multigene Family | 1 | 2020 | 1076 | 0.140 |
Why?
|
Pluripotent Stem Cells | 1 | 2023 | 783 | 0.140 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6453 | 0.140 |
Why?
|
Receptor, Notch1 | 1 | 2019 | 500 | 0.140 |
Why?
|
Garcinia | 1 | 2015 | 3 | 0.130 |
Why?
|
Cisplatin | 3 | 2017 | 1637 | 0.130 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2016 | 155 | 0.130 |
Why?
|
Benzophenones | 1 | 2015 | 54 | 0.130 |
Why?
|
Germ-Line Mutation | 2 | 2020 | 1814 | 0.130 |
Why?
|
Benzoquinones | 1 | 2015 | 200 | 0.120 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9313 | 0.120 |
Why?
|
Methotrexate | 3 | 2022 | 1715 | 0.120 |
Why?
|
Calcium-Binding Proteins | 1 | 2019 | 1057 | 0.120 |
Why?
|
Up-Regulation | 2 | 2021 | 4115 | 0.110 |
Why?
|
Doxorubicin | 2 | 2017 | 2194 | 0.110 |
Why?
|
Cyclohexanones | 1 | 2012 | 29 | 0.100 |
Why?
|
RNA-Binding Proteins | 1 | 2021 | 1885 | 0.100 |
Why?
|
Sp1 Transcription Factor | 1 | 2013 | 141 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 484 | 0.100 |
Why?
|
Genes, bcl-2 | 1 | 2012 | 121 | 0.100 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2013 | 197 | 0.100 |
Why?
|
Plant Extracts | 1 | 2015 | 491 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3525 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2015 | 607 | 0.100 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2014 | 212 | 0.100 |
Why?
|
Cerebellar Neoplasms | 1 | 2016 | 585 | 0.100 |
Why?
|
Prognosis | 5 | 2020 | 29072 | 0.090 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2014 | 646 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2856 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 774 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2017 | 10719 | 0.090 |
Why?
|
Histones | 2 | 2017 | 2552 | 0.090 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3609 | 0.080 |
Why?
|
RNA, Neoplasm | 1 | 2011 | 750 | 0.080 |
Why?
|
Phosphorylation | 2 | 2017 | 8298 | 0.080 |
Why?
|
Cilia | 1 | 2023 | 489 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2777 | 0.080 |
Why?
|
Mice, Knockout | 2 | 2020 | 14212 | 0.080 |
Why?
|
Hedgehog Proteins | 1 | 2023 | 766 | 0.080 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9441 | 0.070 |
Why?
|
Humans | 24 | 2023 | 746070 | 0.070 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1121 | 0.070 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2011 | 1173 | 0.070 |
Why?
|
Osteosarcoma | 1 | 2012 | 875 | 0.070 |
Why?
|
Histone Deacetylases | 1 | 2011 | 706 | 0.070 |
Why?
|
Astrocytoma | 1 | 2011 | 775 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2793 | 0.070 |
Why?
|
Brazil | 2 | 2020 | 1192 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4576 | 0.060 |
Why?
|
Child, Preschool | 6 | 2020 | 41383 | 0.060 |
Why?
|
Receptors, Corticotropin | 1 | 2023 | 24 | 0.060 |
Why?
|
Blotting, Western | 1 | 2011 | 5048 | 0.060 |
Why?
|
RNA, Messenger | 3 | 2014 | 12742 | 0.060 |
Why?
|
NF-kappa B | 1 | 2012 | 2462 | 0.060 |
Why?
|
Frizzled Receptors | 1 | 2023 | 90 | 0.060 |
Why?
|
Vincristine | 2 | 2016 | 1029 | 0.050 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6781 | 0.050 |
Why?
|
Mitotic Index | 2 | 2013 | 161 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3695 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7785 | 0.050 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2023 | 619 | 0.050 |
Why?
|
Animals | 4 | 2022 | 166308 | 0.050 |
Why?
|
Adenoma | 1 | 2012 | 2138 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 4335 | 0.050 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2020 | 38 | 0.050 |
Why?
|
Daunorubicin | 1 | 2020 | 155 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2012 | 2495 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2011 | 2964 | 0.040 |
Why?
|
Infant | 4 | 2016 | 35448 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2013 | 11037 | 0.040 |
Why?
|
Child | 7 | 2019 | 78469 | 0.040 |
Why?
|
Cell Transdifferentiation | 1 | 2020 | 186 | 0.040 |
Why?
|
Embryonic Development | 1 | 2023 | 706 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2013 | 7570 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12272 | 0.040 |
Why?
|
Cell Survival | 2 | 2021 | 5759 | 0.040 |
Why?
|
Mice, Inbred NOD | 1 | 2022 | 1809 | 0.040 |
Why?
|
Cells, Cultured | 1 | 2013 | 18891 | 0.040 |
Why?
|
Rhabdomyosarcoma | 1 | 2020 | 357 | 0.040 |
Why?
|
DNA Methylation | 1 | 2011 | 4259 | 0.040 |
Why?
|
Steroids | 1 | 2021 | 919 | 0.030 |
Why?
|
Cell Cycle | 2 | 2015 | 2921 | 0.030 |
Why?
|
Epigenesis, Genetic | 2 | 2023 | 3655 | 0.030 |
Why?
|
ras Proteins | 1 | 2020 | 1049 | 0.030 |
Why?
|
Point Mutation | 1 | 2020 | 1600 | 0.030 |
Why?
|
Drug Antagonism | 1 | 2014 | 49 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 357 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2023 | 2117 | 0.030 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2015 | 182 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1478 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 1983 | 0.030 |
Why?
|
Lipids | 1 | 2023 | 3290 | 0.030 |
Why?
|
Female | 8 | 2021 | 382129 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 458 | 0.030 |
Why?
|
Drug Interactions | 1 | 2016 | 1413 | 0.030 |
Why?
|
Chromatin | 1 | 2023 | 2896 | 0.020 |
Why?
|
Cell Hypoxia | 1 | 2014 | 659 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 21681 | 0.020 |
Why?
|
Adolescent | 3 | 2016 | 86212 | 0.020 |
Why?
|
Male | 7 | 2021 | 351098 | 0.020 |
Why?
|
Methylation | 1 | 2014 | 1074 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2011 | 352 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2390 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2012 | 371 | 0.020 |
Why?
|
Time Factors | 1 | 2011 | 39589 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2012 | 719 | 0.020 |
Why?
|
Azacitidine | 1 | 2011 | 333 | 0.020 |
Why?
|
Carcinoma | 1 | 2020 | 2344 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3784 | 0.020 |
Why?
|
RNA Splicing | 1 | 2013 | 906 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2014 | 1752 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2011 | 636 | 0.020 |
Why?
|
Cohort Studies | 2 | 2020 | 40505 | 0.020 |
Why?
|
Adult | 5 | 2022 | 214969 | 0.020 |
Why?
|
Protein Transport | 1 | 2012 | 1962 | 0.020 |
Why?
|
Tumor Burden | 1 | 2012 | 1881 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2011 | 1727 | 0.020 |
Why?
|
Age of Onset | 1 | 2012 | 3241 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1405 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2016 | 3411 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 6459 | 0.020 |
Why?
|
Down-Regulation | 1 | 2012 | 2906 | 0.020 |
Why?
|
Mice | 2 | 2022 | 80065 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4858 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6138 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7579 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 21529 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6058 | 0.010 |
Why?
|
Cell Movement | 1 | 2012 | 5161 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2014 | 5164 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 25753 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 57114 | 0.010 |
Why?
|
Middle Aged | 1 | 2021 | 214419 | 0.000 |
Why?
|
Brain | 1 | 2011 | 26597 | 0.000 |
Why?
|